By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity
Enhance the predictive accuracy of cardiac safety assessments to ensure safer drug development and reduce the likelihood of late-stage failures due to cardiac toxicity
Highly-validated screening assays developed by Metrion are capable of confidently identifying modulators of the lysosomal TRPML1 channel.
Improve efficiency, reduce late-stage failures, and align with regulatory standards by assessing the proarrhythmic liability of your compounds early.
The ability to achieve patch-clamp-equivalent data quality using VSD enhances predictive accuracy, reducing false negatives and late-stage failures, and supports safer drug development with improved preclinical-to-clinical translation.
Achieve action potential recordings from intrinsically paced hiPSC-CMs with Metrion’s clinically predictive hiPSC cardiomyocyte assay.